Change in the treatment strategy for pediatric Crohn's disease.
10.3345/kjp.2010.53.9.830
- Author:
Mi Jin KIM
1
;
Yon Ho CHOE
Author Information
1. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. i101016@skku.edu
- Publication Type:Review
- Keywords:
Crohn's disease;
Child;
Treatment
- MeSH:
Adrenal Cortex Hormones;
Antibodies, Monoclonal;
Child;
Crohn Disease;
Gastrointestinal Tract;
Humans;
Inflammation;
Natural History;
Prevalence;
Quality of Life;
Recurrence;
Secondary Prevention;
Infliximab
- From:Korean Journal of Pediatrics
2010;53(9):830-833
- CountryRepublic of Korea
- Language:English
-
Abstract:
Crohn's disease is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Treating Crohn's disease is a major challenge for clinicians, as no curative therapy currently exists. Pediatric Crohn's disease is characterized by frequent relapses, a wide extent of disease, a high prevalence of extraintestinal manifestations, and a severe clinical course. The classic therapeutic approach is known as the 'step-up' strategy, and follows a progressive course of treatment intensification as disease severity increases. Although this approach is usually effective for symptom control, many patients become either resistant to or dependent on corticosteroids. The efficacy of infliximab suggests that, rather than a progressive course of treatment, early intense induction may reduce complications associated with conventional treatment and improve quality of life. Intensive early therapy with infliximab is known as the 'top-down' strategy. Such therapy offers the potential for altering the natural history of Crohn's disease, and is changing treatment paradigms. However, the relatively new concept of an early aggressive or 'top-down' treatment approach is not yet widely accepted, especially in pediatric patients. The results of our current study demonstrate that early and intensive treatment of pediatric Crohn's disease patients with infliximab, at initial diagnosis, was more effective for maintaining remission and reducing flares.
